

Gerwyn Morris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3790971/publications.pdf>

Version: 2024-02-01

63
papers

3,822
citations

117625

34
h-index

133252

59
g-index

63
all docs

63
docs citations

63
times ranked

5450
citing authors

#	ARTICLE	IF	CITATIONS
1	Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis. <i>Molecular Neurobiology</i> , 2018, 55, 4195-4206.	4.0	279
2	Post-Operative Cognitive Dysfunction: An exploration of the inflammatory hypothesis and novel therapies. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 116-133.	6.1	210
3	The Role of the Microbial Metabolites Including Tryptophan Catabolites and Short Chain Fatty Acids in the Pathophysiology of Immune-Inflammatory and Neuroimmune Disease. <i>Molecular Neurobiology</i> , 2017, 54, 4432-4451.	4.0	191
4	The many roads to mitochondrial dysfunction in neuroimmune and neuropsychiatric disorders. <i>BMC Medicine</i> , 2015, 13, 68.	5.5	186
5	The Glutathione System: A New Drug Target in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2014, 50, 1059-1084.	4.0	164
6	Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. <i>BMC Medicine</i> , 2013, 11, 205.	5.5	121
7	Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses. <i>BMC Medicine</i> , 2015, 13, 28.	5.5	121
8	A model of the mitochondrial basis of bipolar disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 74, 1-20.	6.1	118
9	The Neuro-Immune Pathophysiology of Central and Peripheral Fatigue in Systemic Immune-Inflammatory and Neuro-Immune Diseases. <i>Molecular Neurobiology</i> , 2016, 53, 1195-1219.	4.0	115
10	Why should neuroscientists worry about iron? The emerging role of ferroptosis in the pathophysiology of neuroprogressive diseases. <i>Behavioural Brain Research</i> , 2018, 341, 154-175.	2.2	114
11	Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists. <i>Molecular Neurobiology</i> , 2018, 55, 5767-5786.	4.0	114
12	Mitochondrial dysfunctions in Myalgic Encephalomyelitis / chronic fatigue syndrome explained by activated immuno-inflammatory, oxidative and nitrosative stress pathways. <i>Metabolic Brain Disease</i> , 2014, 29, 19-36.	2.9	109
13	Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS). <i>Current Neuropharmacology</i> , 2014, 12, 168-185.	2.9	103
14	A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. <i>Metabolic Brain Disease</i> , 2013, 28, 523-540.	2.9	92
15	Leaky brain in neurological and psychiatric disorders: Drivers and consequences. <i>Australian and New Zealand Journal of Psychiatry</i> , 2018, 52, 924-948.	2.3	90
16	The putative role of oxidative stress and inflammation in the pathophysiology of sleep dysfunction across neuropsychiatric disorders: Focus on chronic fatigue syndrome, bipolar disorder and multiple sclerosis. <i>Sleep Medicine Reviews</i> , 2018, 41, 255-265.	8.5	85
17	Nitrosative Stress, Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. <i>Molecular Neurobiology</i> , 2017, 54, 4271-4291.	4.0	82
18	The pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach. <i>Life Sciences</i> , 2020, 258, 118166.	4.3	79

#	ARTICLE	IF	CITATIONS
19	Hypothalamic-Pituitary-Adrenal Hypofunction in Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS) as a Consequence of Activated Immune-Inflammatory and Oxidative and Nitrosative Pathways. <i>Molecular Neurobiology</i> , 2017, 54, 6806-6819.	4.0	77
20	Shared pathways for neuroprogression and somatoprogession in neuropsychiatric disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2019, 107, 862-882.	6.1	74
21	Could Alzheimer's Disease Originate in the Periphery and If So How So?. <i>Molecular Neurobiology</i> , 2019, 56, 406-434.	4.0	71
22	A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. <i>BMC Medicine</i> , 2013, 11, 64.	5.5	62
23	The cytokine storms of COVID-19, H1N1 influenza, CRS and MAS compared. Can one sized treatment fit all?. <i>Cytokine</i> , 2021, 144, 155593.	3.2	61
24	The Endoplasmic Reticulum Stress Response in Neuroprogressive Diseases: Emerging Pathophysiological Role and Translational Implications. <i>Molecular Neurobiology</i> , 2018, 55, 8765-8787.	4.0	59
25	The putative role of environmental aluminium in the development of chronic neuropathology in adults and children. How strong is the evidence and what could be the mechanisms involved?. <i>Metabolic Brain Disease</i> , 2017, 32, 1335-1355.	2.9	57
26	Endothelial dysfunction in neuroprogressive disorders—causes and suggested treatments. <i>BMC Medicine</i> , 2020, 18, 305.	5.5	53
27	Multiple Immune-Inflammatory and Oxidative and Nitrosative Stress Pathways Explain the Frequent Presence of Depression in Multiple Sclerosis. <i>Molecular Neurobiology</i> , 2018, 55, 6282-6306.	4.0	51
28	Myalgic encephalomyelitis or chronic fatigue syndrome: how could the illness develop?. <i>Metabolic Brain Disease</i> , 2019, 34, 385-415.	2.9	50
29	Increased nuclear factor- κ B and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). <i>Medical Hypotheses</i> , 2012, 79, 607-613.	1.5	49
30	The Deleterious Effects of Oxidative and Nitrosative Stress on Palmitoylation, Membrane Lipid Rafts and Lipid-Based Cellular Signalling: New Drug Targets in Neuroimmune Disorders. <i>Molecular Neurobiology</i> , 2016, 53, 4638-4658.	4.0	49
31	Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry. <i>Molecular Neurobiology</i> , 2021, 58, 2158-2182.	4.0	48
32	Socioeconomic Deprivation, Adverse Childhood Experiences and Medical Disorders in Adulthood: Mechanisms and Associations. <i>Molecular Neurobiology</i> , 2019, 56, 5866-5890.	4.0	46
33	Preventing the development of severe COVID-19 by modifying immunothrombosis. <i>Life Sciences</i> , 2021, 264, 118617.	4.3	40
34	The Toll-Like Receptor Radical Cycle Pathway: A New Drug Target in Immune-Related Chronic Fatigue. <i>CNS and Neurological Disorders - Drug Targets</i> , 2015, 14, 838-854.	1.4	39
35	Emerging role of innate B1 cells in the pathophysiology of autoimmune and neuroimmune diseases: Association with inflammation, oxidative and nitrosative stress and autoimmune responses. <i>Pharmacological Research</i> , 2019, 148, 104408.	7.1	35
36	Do Human Endogenous Retroviruses Contribute to Multiple Sclerosis, and if So, How?. <i>Molecular Neurobiology</i> , 2019, 56, 2590-2605.	4.0	33

#	ARTICLE	IF	CITATIONS
37	Myalgic encephalomyelitis/chronic fatigue syndrome: From pathophysiological insights to novel therapeutic opportunities. <i>Pharmacological Research</i> , 2019, 148, 104450.	7.1	31
38	Nutritional ketosis as an intervention to relieve astrogliosis: Possible therapeutic applications in the treatment of neurodegenerative and neuroprogressive disorders. <i>European Psychiatry</i> , 2020, 63, e8.	0.2	31
39	The interplay between oxidative stress and bioenergetic failure in neuropsychiatric illnesses: can we explain it and can we treat it?. <i>Molecular Biology Reports</i> , 2020, 47, 5587-5620.	2.3	29
40	The role of high-density lipoprotein cholesterol, apolipoprotein A and paraoxonase-1 in the pathophysiology of neuroprogressive disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 125, 244-263.	6.1	29
41	The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability. <i>Molecular Neurobiology</i> , 2016, 53, 2550-2571.	4.0	28
42	Induced Ketosis as a Treatment for Neuroprogressive Disorders: Food for Thought?. <i>International Journal of Neuropsychopharmacology</i> , 2020, 23, 366-384.	2.1	28
43	The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 84, 453-469.	6.1	27
44	The role of microglia in neuroprogressive disorders: mechanisms and possible neurotherapeutic effects of induced ketosis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109858.	4.8	26
45	A Comparison of Neuroimaging Abnormalities in Multiple Sclerosis, Major Depression and Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): is There a Common Cause?. <i>Molecular Neurobiology</i> , 2018, 55, 3592-3609.	4.0	25
46	The endocannabinoidome in neuropsychiatry: Opportunities and potential risks. <i>Pharmacological Research</i> , 2021, 170, 105729.	7.1	24
47	The Putative Role of Environmental Mercury in the Pathogenesis and Pathophysiology of Autism Spectrum Disorders and Subtypes. <i>Molecular Neurobiology</i> , 2018, 55, 4834-4856.	4.0	22
48	Case definitions and diagnostic criteria for Myalgic Encephalomyelitis and Chronic fatigue Syndrome: from clinical-consensus to evidence-based case definitions. <i>Neuroendocrinology Letters</i> , 2013, 34, 185-99.	0.2	22
49	Imaging genetics paradigms in depression research: Systematic review and meta-analysis. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 86, 102-113.	4.8	19
50	The compensatory antioxidant response system with a focus on neuroprogressive disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 95, 109708.	4.8	19
51	Polyphenols as adjunctive treatments in psychiatric and neurodegenerative disorders: Efficacy, mechanisms of action, and factors influencing inter-individual response. <i>Free Radical Biology and Medicine</i> , 2021, 172, 101-122.	2.9	19
52	Inflammation and Nitro-oxidative Stress as Drivers of Endocannabinoid System Aberrations in Mood Disorders and Schizophrenia. <i>Molecular Neurobiology</i> , 2022, 59, 3485-3503.	4.0	19
53	Statins: Neurobiological underpinnings and mechanisms in mood disorders. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 693-708.	6.1	15
54	Can endolysosomal deacidification and inhibition of autophagy prevent severe COVID-19?. <i>Life Sciences</i> , 2020, 262, 118541.	4.3	12

#	ARTICLE	IF	CITATIONS
55	Transcriptional Modulation of the Hippo Signaling Pathway by Drugs Used to Treat Bipolar Disorder and Schizophrenia. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7164.	4.1	11
56	The lipid paradox in neuroprogressive disorders: Causes and consequences. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 128, 35-57.	6.1	10
57	Increased ACE2, sRAGE, and Immune Activation, but Lowered Calcium and Magnesium in COVID-19. <i>Recent Advances in Inflammation & Allergy Drug Discovery</i> , 2022, 16, 32-43.	0.8	10
58	Cysteine proteinase inhibitors and bleomycin-sensitive and -resistant cells. <i>Biochemical Pharmacology</i> , 1991, 41, 1559-1566.	4.4	8
59	Is a diagnostic blood test for chronic fatigue syndrome on the horizon?. <i>Expert Review of Molecular Diagnostics</i> , 2019, 19, 1049-1051.	3.1	8
60	Potential therapeutic interventions based on the role of the endoplasmic reticulum stress response in progressive neurodegenerative diseases. <i>Neural Regeneration Research</i> , 2018, 13, 1887.	3.0	7
61	Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2022, 114, 110481.	4.8	6
62	Neutralization of bleomycin hydrolase by an epitope-specific antibody. <i>Molecular Pharmacology</i> , 1992, 42, 57-62.	2.3	6
63	Decreased C-MYC and BCL2 Expression Correlates with Methylprednisolone-Mediated Inhibition of Raji Lymphoma Growth. <i>Biochemical and Molecular Medicine</i> , 1997, 60, 108-115.	1.4	4